Latest Insider Transactions at Merck & Co., Inc. (MRK)
This section provides a real-time view of insider transactions for Merck & Co., Inc. (MRK). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Merck & Co., Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Merck & Co., Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 19
2019
|
Kenneth C Frazier Executive Chair |
BUY
Exercise of conversion of derivative security
|
Direct |
42,700
+5.49%
|
$1,665,300
$39.29 P/Share
|
|
Feb 15
2019
|
Kenneth C Frazier Executive Chair |
SELL
Open market or private sale
|
Direct |
92,913
-11.84%
|
$7,433,040
$80.03 P/Share
|
|
Feb 15
2019
|
Kenneth C Frazier Executive Chair |
BUY
Exercise of conversion of derivative security
|
Direct |
92,913
+10.59%
|
$3,623,607
$39.29 P/Share
|
|
Feb 14
2019
|
Rita A Karachun Sr. VP Fince-Global Controller |
SELL
Open market or private sale
|
Direct |
64,662
-79.99%
|
$5,043,636
$78.96 P/Share
|
|
Feb 14
2019
|
Rita A Karachun Sr. VP Fince-Global Controller |
BUY
Exercise of conversion of derivative security
|
Direct |
64,662
+33.23%
|
$3,815,058
$59.04 P/Share
|
|
Feb 13
2019
|
Wendell P Weeks Director |
SELL
Open market or private sale
|
Direct |
5,000
-98.04%
|
$390,000
$78.71 P/Share
|
|
Feb 13
2019
|
Wendell P Weeks Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+49.51%
|
$120,000
$24.3 P/Share
|
|
Feb 12
2019
|
Sanat Chattopadhyay Exe V-P & Pres. MMD |
SELL
Open market or private sale
|
Direct |
73,727
-58.89%
|
$5,750,706
$78.62 P/Share
|
|
Feb 12
2019
|
Sanat Chattopadhyay Exe V-P & Pres. MMD |
BUY
Exercise of conversion of derivative security
|
Direct |
73,727
+25.38%
|
$2,727,899
$37.93 P/Share
|
|
Feb 08
2019
|
Leslie A Brun Director |
SELL
Open market or private sale
|
Direct |
3,052
-61.04%
|
$235,004
$77.22 P/Share
|
|
Feb 08
2019
|
Leslie A Brun Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+50.0%
|
$120,000
$24.3 P/Share
|
|
Feb 05
2019
|
Kenneth C Frazier Executive Chair |
SELL
Open market or private sale
|
Direct |
231,566
-25.07%
|
$18,062,148
$78.08 P/Share
|
|
Feb 05
2019
|
Kenneth C Frazier Executive Chair |
BUY
Exercise of conversion of derivative security
|
Direct |
231,566
+20.05%
|
$9,031,074
$39.29 P/Share
|
|
Feb 04
2019
|
Thomas H Glocer Director |
SELL
Open market or private sale
|
Direct |
10,000
-66.23%
|
$750,000
$75.96 P/Share
|
|
Feb 04
2019
|
Thomas H Glocer Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+28.99%
|
$290,000
$29.74 P/Share
|
|
Nov 08
2018
|
Roger M Perlmutter Exe V-P & Pres, MRL |
SELL
Open market or private sale
|
Direct |
225,443
-61.43%
|
$16,908,225
$75.27 P/Share
|
|
Nov 08
2018
|
Roger M Perlmutter Exe V-P & Pres, MRL |
BUY
Exercise of conversion of derivative security
|
Direct |
225,443
+38.05%
|
$9,919,492
$44.98 P/Share
|
|
Nov 07
2018
|
Julie L. Gerberding EVP, Chief Patient Officer |
SELL
Open market or private sale
|
Direct |
36,218
-43.91%
|
$2,716,350
$75.14 P/Share
|
|
Nov 07
2018
|
Julie L. Gerberding EVP, Chief Patient Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
36,218
+30.51%
|
$1,955,772
$54.68 P/Share
|
|
Nov 01
2018
|
Adam H Schechter EVP & Pres-Global Human Health |
SELL
Open market or private sale
|
Direct |
277,879
-73.89%
|
$20,285,167
$73.82 P/Share
|
|
Nov 01
2018
|
Adam H Schechter EVP & Pres-Global Human Health |
BUY
Exercise of conversion of derivative security
|
Direct |
277,879
+50.0%
|
$10,837,281
$39.29 P/Share
|
|
Oct 31
2018
|
Ashley Watson SVP Chief Ethics & Com Officer |
SELL
Open market or private sale
|
Direct |
47,036
-82.8%
|
$3,480,664
$74.33 P/Share
|
|
Oct 31
2018
|
Ashley Watson SVP Chief Ethics & Com Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
47,036
+25.53%
|
$2,775,124
$59.5 P/Share
|
|
Oct 30
2018
|
Richard R. De Luca EVP&Pres, Merck Animal Heallth |
SELL
Open market or private sale
|
Direct |
25,467
-31.01%
|
$1,833,624
$72.0 P/Share
|
|
Oct 30
2018
|
Richard R. De Luca EVP&Pres, Merck Animal Heallth |
BUY
Exercise of conversion of derivative security
|
Direct |
25,467
+23.67%
|
$865,878
$34.19 P/Share
|
|
Oct 02
2018
|
Kenneth C Frazier Executive Chair |
SELL
Open market or private sale
|
Direct |
279,850
-28.8%
|
$20,149,200
$72.07 P/Share
|
|
Oct 02
2018
|
Kenneth C Frazier Executive Chair |
BUY
Exercise of conversion of derivative security
|
Direct |
279,850
+22.36%
|
$10,074,600
$36.56 P/Share
|
|
Sep 18
2018
|
Kenneth C Frazier Executive Chair |
SELL
Open market or private sale
|
Direct |
279,851
-28.8%
|
$19,589,570
$70.08 P/Share
|
|
Sep 18
2018
|
Kenneth C Frazier Executive Chair |
BUY
Exercise of conversion of derivative security
|
Direct |
279,851
+22.36%
|
$10,074,636
$36.56 P/Share
|
|
Sep 17
2018
|
Adam H Schechter EVP & Pres-Global Human Health |
SELL
Open market or private sale
|
Indirect |
7,360
-11.73%
|
$515,200
$70.18 P/Share
|
|
Sep 17
2018
|
Adam H Schechter EVP & Pres-Global Human Health |
SELL
Open market or private sale
|
Direct |
100,000
-100.0%
|
$7,000,000
$70.18 P/Share
|
|
Sep 17
2018
|
Adam H Schechter EVP & Pres-Global Human Health |
BUY
Exercise of conversion of derivative security
|
Direct |
100,000
+50.0%
|
$3,600,000
$36.56 P/Share
|
|
Aug 03
2018
|
Sanat Chattopadhyay Exe V-P & Pres. MMD |
SELL
Open market or private sale
|
Direct |
29,208
-36.2%
|
$1,898,520
$65.2 P/Share
|
|
Aug 03
2018
|
Sanat Chattopadhyay Exe V-P & Pres. MMD |
BUY
Exercise of conversion of derivative security
|
Direct |
29,208
+16.2%
|
$1,022,280
$35.49 P/Share
|
|
Aug 02
2018
|
Rita A Karachun Sr. VP Fince-Global Controller |
SELL
Open market or private sale
|
Direct |
5,000
-23.61%
|
$325,000
$65.01 P/Share
|
|
Jul 31
2018
|
Kenneth C Frazier Executive Chair |
SELL
Bona fide gift
|
Direct |
18,747
-2.64%
|
-
|
|
Jul 31
2018
|
Kenneth C Frazier Executive Chair |
SELL
Open market or private sale
|
Direct |
228,091
-24.3%
|
$14,825,915
$65.0 P/Share
|
|
Jul 31
2018
|
Kenneth C Frazier Executive Chair |
BUY
Exercise of conversion of derivative security
|
Direct |
228,091
+19.55%
|
$7,527,003
$33.49 P/Share
|
|
Jun 18
2018
|
Adam H Schechter EVP & Pres-Global Human Health |
SELL
Open market or private sale
|
Indirect |
34,094
-35.2%
|
$2,079,734
$61.0 P/Share
|
|
Jun 18
2018
|
Adam H Schechter EVP & Pres-Global Human Health |
SELL
Open market or private sale
|
Direct |
100,000
-100.0%
|
$6,100,000
$61.0 P/Share
|
|
Jun 18
2018
|
Adam H Schechter EVP & Pres-Global Human Health |
BUY
Exercise of conversion of derivative security
|
Direct |
100,000
+50.0%
|
$3,600,000
$36.56 P/Share
|
|
May 15
2018
|
Julie L. Gerberding EVP, Chief Patient Officer |
SELL
Open market or private sale
|
Direct |
9,972
-17.91%
|
$588,348
$59.66 P/Share
|
|
May 01
2018
|
Sanat Chattopadhyay Exe V-P & Pres. MMD |
SELL
Payment of exercise price or tax liability
|
Direct |
1,142
-2.17%
|
$66,236
$58.87 P/Share
|
|
May 01
2018
|
Sanat Chattopadhyay Exe V-P & Pres. MMD |
BUY
Exercise of conversion of derivative security
|
Direct |
4,009
+7.08%
|
-
|
|
May 01
2018
|
Rita A Karachun Sr. VP Fince-Global Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
1,030
-4.64%
|
$59,740
$58.87 P/Share
|
|
May 01
2018
|
Rita A Karachun Sr. VP Fince-Global Controller |
BUY
Exercise of conversion of derivative security
|
Direct |
3,007
+11.93%
|
-
|
|
May 01
2018
|
Ashley Watson SVP Chief Ethics & Com Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,151
-24.65%
|
$182,758
$58.87 P/Share
|
|
May 01
2018
|
Ashley Watson SVP Chief Ethics & Com Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,441
+44.96%
|
-
|
|
Apr 16
2018
|
Weir Mirian M Graddick Exe V-P, HR |
SELL
Open market or private sale
|
Direct |
24,000
-22.98%
|
$1,392,000
$58.0 P/Share
|
|
Feb 27
2018
|
Adam H Schechter EVP & Pres-Global Human Health |
BUY
Grant, award, or other acquisition
|
Direct |
34,094
+50.0%
|
$1,841,076
$54.72 P/Share
|